Abstract
To test the relationship between plasma moricizine concentration and the electrocardiogram (ECG) and arrhythmia suppression, 17 symptomatic cardiac patients with 30 or more ventricular premature complexes per hour were studied. Seven patients were mature adults, less than 60 years of age; and ten were elderly adults, more than 60 years of age. During steady-state moricizine therapy, patients had plasma moricizine concentration determined over a dosing interval, and had standard 12-lead ECG and a 24-hour ambulatory ECG recorded. The mean moricizine dose was 215 +/- 29 mg every 8 hours; mean maximal moricizine concentration was 1.4 +/- 0.84 micrograms/ml; and mean t1/2 beta was 1.5 +/- 0.7 hours. Baseline age-related differences were found, including prolonged electrocardiographic intervals (PR and QRS) (P < .05), increased ventricular arrhythmias (P < .05), and reduction in creatinine clearance (P < .05) in the elderly. Compared with pretreatment values, PR (P < .05) and QRS (P < .05) prolongation was observed, and was more marked in elderly patients. Over a dosing interval, there were dynamic changes on the ECG that paralleled plasma moricizine concentration; that is, peak and nadir intact moricizine concentration occurred simu...Continue Reading
References
Sep 1, 1978·The American Journal of Cardiology·H R OchsT W Smith
Jan 1, 1979·British Journal of Clinical Pharmacology·C M Castleden, C F George
Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators
Jan 1, 1990·American Heart Journal·C M PrattS Mahler
Jun 1, 1991·Journal of the American College of Cardiology·M E WechslerE G Giardina
Mar 1, 1992·Annals of Internal Medicine·R DamleA H Kadish
Mar 1, 1992·Annals of Internal Medicine·A C PowellB A McGovern
Nov 1, 1990·Clinical Pharmacology and Therapeutics·E V GiardinaM Schneider
Feb 20, 1990·The American Journal of Cardiology·L A SiddowayR L Woosley
Apr 15, 1986·The American Journal of Cardiology·K GearR Serokman
Apr 1, 1989·Annals of Internal Medicine·S S GottliebM Packer
Nov 1, 1989·Journal of the American College of Cardiology·S RavidB Lown
Mar 15, 1989·The American Journal of Cardiology·P J PodridM P Klein
Jan 31, 1986·The American Journal of Cardiology·R L WoosleyD M Roden
Aug 1, 1987·Journal of the American College of Cardiology·J A HerdR Harris
Aug 1, 1987·Clinical Pharmacology and Therapeutics·D M SalernoM Hodges
Jan 1, 1987·European Journal of Clinical Pharmacology·D L HowrieL W Dittert
Oct 16, 1987·The American Journal of Cardiology·R L WoosleyR L Williams
May 1, 1987·The American Journal of Cardiology·J B Schwartz, D R Abernethy
Sep 1, 1986·Annals of Internal Medicine·D R AbernethyE Snow
Mar 1, 1985·Journal of Clinical Pharmacology·R T MacFarlandF I Marcus
Jun 1, 1985·Clinical Pharmacology and Therapeutics·J BiollazA J Wood
Feb 1, 1984·Circulation·C M PrattR Roberts
Apr 1, 1981·Journal of Pharmaceutical Sciences·C C WhitneyJ C Gaylord
Feb 1, 1982·British Journal of Clinical Pharmacology·P C RubinJ L Reid
Feb 1, 1980·Circulation·P J PodridN Mazur
Jan 1, 1980·Clinical Pharmacology and Therapeutics·D E DrayerM M Reidenberg
Mar 13, 1980·The New England Journal of Medicine·P J PodridB Lown